Enterprise Value

3.964B

Cash

625.7M

Avg Qtr Burn

-155.7M

Short % of Float

16.34%

Insider Ownership

13.63%

Institutional Own.

96.76%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Empaveli (systemic pegcetacoplan) (APL-2) Details
Paroxysmal nocturnal hemoglobinuria

Approved

Quarterly sales

SYFOVRE™(Intravitreal pegcetacoplan) Details
Geographic atrophy, Age-related macular degeneration

Approved

Quarterly sales

Phase 3

Data readout

Systemic pegcetacoplan (APL-2) Details
Immune complex membranoproliferative glomerulonephritis, C3 Glomerulopathy

Phase 3

Data readout

Systemic pegcetacoplan (APL-2) Details
Hematopoietic stem cell transplantation thrombotic microangiopathies

Phase 2

Data readout

Intravenous APL-9 Details
ARDS (Acute respiratory distress syndrome), TMA (Thrombotic microangiopathies)

Failed

Discontinued

Systemic pegcetacoplan (APL-2) Details
Amyotrophic lateral sclerosis

Failed

Discontinued